Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.

Alakhras NS, Qiu J, Rocha GV, Witcher DR, Koester A, You J, Schaer DA, Holmgaard RB, Driscoll K, Willy JA, Malherbe LP.

MAbs. 2018 Aug/Sep;10(6):913-921. doi: 10.1080/19420862.2018.1474996. Epub 2018 Jul 26.

PMID:
29953319
2.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.

Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE.

J Immunother Cancer. 2018 Jun 4;6(1):47. doi: 10.1186/s40425-018-0356-4.

3.

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, Wang YC, Rasmussen ER, Chin D, Capen A, Carpenito C, Staschke KA, Chung LA, Litchfield LM, Merzoug FF, Gong X, Iversen PW, Buchanan S, de Dios A, Novosiadly RD, Kalos M.

Cell Rep. 2018 Mar 13;22(11):2978-2994. doi: 10.1016/j.celrep.2018.02.053.

4.

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.

Budhu S, Schaer DA, Li Y, Toledo-Crow R, Panageas K, Yang X, Zhong H, Houghton AN, Silverstein SC, Merghoub T, Wolchok JD.

Sci Signal. 2017 Aug 29;10(494). pii: eaak9702. doi: 10.1126/scisignal.aak9702.

5.

Platelet membrane potential: unable to pull the plug on sepsis.

Schaer DA, Penn J, Jagpal S, Parikh A.

Crit Care. 2014 May 12;18(3):428. doi: 10.1186/cc13869. No abstract available.

6.

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy.

Schaer DA, Hirschhorn-Cymerman D, Wolchok JD.

J Immunother Cancer. 2014 Apr 15;2:7. doi: 10.1186/2051-1426-2-7. eCollection 2014. Review.

7.

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T, Wolchok JD.

Cancer Immunol Res. 2013 Nov;1(5):320-31. doi: 10.1158/2326-6066.CIR-13-0086.

8.

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.

Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD.

Clin Cancer Res. 2013 Mar 1;19(5):1009-20. doi: 10.1158/1078-0432.CCR-12-2982.

9.

Modulation of GITR for cancer immunotherapy.

Schaer DA, Murphy JT, Wolchok JD.

Curr Opin Immunol. 2012 Apr;24(2):217-24. doi: 10.1016/j.coi.2011.12.011. Epub 2012 Jan 12. Review.

10.

Hiding the road signs that lead to tumor immunity.

Schaer DA, Lesokhin AM, Wolchok JD.

J Exp Med. 2011 Sep 26;208(10):1937-40. doi: 10.1084/jem.20111856. Review.

11.

Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope.

Schaer DA, Li Y, Merghoub T, Rizzuto GA, Shemesh A, Cohen AD, Li Y, Avogadri F, Toledo-Crow R, Houghton AN, Wolchok JD.

PLoS One. 2011;6(6):e21214. doi: 10.1371/journal.pone.0021214. Epub 2011 Jun 22.

12.

Anti-GITR antibodies--potential clinical applications for tumor immunotherapy.

Schaer DA, Cohen AD, Wolchok JD.

Curr Opin Investig Drugs. 2010 Dec;11(12):1378-86. Review.

PMID:
21154120
13.

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.

Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD.

PLoS One. 2010 May 3;5(5):e10436. doi: 10.1371/journal.pone.0010436.

Supplemental Content

Loading ...
Support Center